1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Analysis & Statistics 2020 - Brazil

Pharmaceutical Analysis & Statistics 2020 - Brazil

Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

Publishers

  • All
    • Datamonitor Healthcare

All regions

  • All
    • Latin America
      • Brazil

data types

1-6 of 6 reports

Drug Overview: TetraVax-DV

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview  TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine currently in Phase II/III development. The viral strains were formulated by the US National Institutes of ...

  • Pharmaceutical
  • Therapy
  • Vaccine
  • Brazil
  • Forecast

Drug Overview: TAK-003

  • $ 10000
  • January 2018
  • 18 pages

Drug Overview  TAK-003 (Takeda) is a needle-free, tetravalent live-attenuated vaccine currently in Phase II/III development in the US and dengue-endemic countries in Asia and Latin America, including ...

  • Pharmaceutical
  • Therapy
  • Vaccine
  • Brazil
  • Forecast

Drug Analysis: TetraVax-DV

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine currently in Phase II/III development. The viral strains were formulated by the US National Institutes of Health ...

  • Pharmaceutical
  • Therapy
  • Vaccine
  • Brazil
  • Forecast

Drug Analysis: TAK-003

  • $ 10000
  • January 2018
  • 18 pages

Drug Overview TAK-003 (Takeda) is a needle-free, tetravalent live-attenuated vaccine currently in Phase II/III development in the US and dengue-endemic countries in Asia and Latin America, including Brazil, ...

  • Pharmaceutical
  • Therapy
  • Vaccine
  • Brazil
  • Forecast

Dengue vaccines

  • $ 5000
  • October 2015
  • 156 pages

Dengvaxia’s ability to reduce the clinical and economic burden of dengue infection will ensure the rollout of vaccination programs in endemic markets, with sales expected to grow until the 2019 launches ...

  • Pharmaceutical
  • Brazil
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited

Access in Emerging Markets: HTA is Making Inroads

  • $ 7500
  • April 2015
  • 119 pages

Faced with tough competitive conditions and declining growth rates, many pharma companies are looking towards emerging markets as sources of revenue growth. Growing economies and a burgeoning middle class, ...

  • Healthcare
  • Pharmaceutical
  • Brazil
  • Taiwan
  • Quintiles Transnational Holdings Inc.



Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on